[Effects of recombinant human granulocyte colony-stimulating factor on superoxide production by neutrophil in cancer patients receiving chemotherapy].
The in vivo effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on the number and function of peripheral neutrophils were studied in time sequence in 9 cancer patients receiving anticancer cytotoxic chemotherapy; 6 patients with transitional cell carcinoma of urothelium treated with CAP (the combination of cyclophosphamide, adriamycin and cisplatin) and the other 3 with testicular tumor treated with PEB (the combination of cisplatin, etoposide and bleomycin). The neutrophil function was evaluated by superoxide production, measuring chemiluminescence of the neutrophil suspension by a photometer. In the 1st course, when no rhG-CSF was administered, the neutrophil function declined significantly (p < 0.01) as the peripheral neutrophil count (PNC) decreased, reached the minimum almost at the same day as PNC reached the nadir, and returned to the normal level at the beginning of the next course. In the 2nd course, when rhG-CSF (75 micrograms/body) was administered subcutaneously daily for 14 consecutive days beginning at 72 hours after the chemotherapy, the nadir of neutropenia was elevated (p < 0.01), the period of neutropenia (< 1,000/mm3) was shortened (p < 0.01), the recovery from neutropenia (> 1,500/mm3) was accelerated (p < 0.01) as compared to the 1st course, and an marked increase of PNC (p < 0.01) to the peak on the next day of the last administration of rhG-CSF was observed. In addition, deterioration of neutrophil function was alleviated (p < 0.05) and the neutrophil function was enhanced (p < 0.01-0.05) during rhG-CSF administration, even at the nadir of neutropenia.(ABSTRACT TRUNCATED AT 250 WORDS)
Yoshida
M
M
Department of Urology, Faculty of Medicine, University of Tokyo.
Oshi
M
M
Aso
Y
Y
Yanagisawa
R
R
Kishi
H
H
Ishida
Y
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009504:Neutrophils / Q000378:metabolism*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013481:Superoxides / Q000378:metabolism*; D014565:Urogenital Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D011994:Recombinant Proteins; D013481:Superoxides; D016179:Granulocyte Colony-Stimulating Factor; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin